Dr. Harriet Feilotter - Ontario Institute for Cancer Research

Learn about our new CATALYST Funding Opportunity

Research > Researchers

Dr. Harriet Feilotter

Contact

Dr. Harriet Feilotter

Ontario Molecular Pathology Research Network Director and Lead, Clinical Implementation

hf4@queensu.ca

Ontario Molecular Pathology Research Network Director and Lead, Clinical Implementation

Dr. Harriet Feilotter’s research focuses on the implementation of biomarkers to be used in the screening, diagnosis or treatment of human diseases, including cancer.

External Links

Using her dual role as a researcher in Pathology and Molecular Medicine, and service chief of laboratory genetics at the Kingston Health Sciences Center, her research is geared towards clinical applications of targeted biomarkers.

Her research includes the study of DNA, RNA and protein biomarkers in a variety of diseases including breast, lung, melanoma, bladder and colon cancers. The Feilotter Lab makes use of multiple platforms, including massively parallel sequencing, to generate and validate targeted biomarker data. Her primary focus is in developing and standardizing pathways for the effective implementation of robustly evaluated biomarkers in the clinical setting, including the assessment of quality metrics. To that end, she engages in community ring studies to assess methodology for evaluation of analytic parameters for targeted molecular assays. Due to the networked nature of the work, she also has an interest and focus in informatics, including the proper handling, storage and sharing of biomarker data, the preprocessing pipelines required to ensure high quality data, the analytic pipelines needed to deliver an effective clinical tool and the ability to federate multiple types of data into formats suitable for sharing, querying and storing.

Experience & Education

Genetics Consultant, St. Michael’s Hospital, Toronto
Acting Clinical Chief, Genetics, Laboratory Medicine, Eastern Health, Newfoundland
Assistant/Associate Professor, Dept. of Pathology and Molecular Medicine, Queen’s University
CCMG Fellow, Kingston General Hospital
Post doctoral research fellow, Cold Spring Harbor Laboratory
PhD research, Dept. of Microbiology, University of Oxford
PhD candidate, Dept. of Biology, Queen’s University
M.Sc. candidate, Dept. of Biology, Queen’s University

Current Affiliations

Lead, Clinical Implementation, OICR
Senior Scientist, Canadian Clinical Trials Group
Chief Scientific Officer and member, Indoc Research
Professor, Dept. of Pathology and Molecular Medicine, Queen’s University
Service Chief, Division of Laboratory Genetics, Kingston Health Sciences Center
Director, Molecular Genetics Laboratory, Kingston Health Sciences Center
Associate Member, Cancer Research Institute, Queen’s University
Chair, Molecular Oncology Advisory Committee, Cancer Care Ontario

Select Publications

Malone ER, Saleh RR, Yu C, …, Feilotter H, …, Bedard P. OCTANE (Ontario-wide Cancer Targeted Nucleic Acid Evaluation): a platform for intraprovincial, national, and international clinical data-sharing. Curr Oncol. 2019;26(5):e618-e623.
Hume S, Nelson TN, Speevak M, …, Feilotter H, …, Stockley TL. CCMG practice guideline: laboratory guidelines for next-generation sequencing. J Med Genet. 2019;56(12):792-800.
Levy MA, Santos S, Kerkhof J, …, Feilotter H, …, Sadikovic B. Implementation of an NGS-based sequencing and gene fusion panel for clinical screening of patients with suspected hematologic malignancies. Eur J Haematol. 2019;103(3):178-189.
Kim HK, Tyryshkin K, Elmi N, …, Feilotter H. Plasma microRNA expression levels and their targeted pathways in patients with major depressive disorder who are responsive to duloxetine treatment. J Psychiatr Res. 2019;110:38-44.
Vaughn C, Costa J, Feilotter HE, …, Laurent-Puig P. Simultaneous detection of lung fusions using a multiplex RT-PCR next generation sequencing-based approach: a multi-institutional research study. BMC Cancer. 2018; 18:828.
Bradbury P, Morris D, Nicholas G, …, Feilotter HE, Seymour L, Laurie S. Canadian Cancer Trials Group (CCTG) IND211: A randomized trial of reolysin in patients with previously treated advanced or metastatic non-small cell lung cancer receiving standard salvage therapy. Lung Cancer. 2018; 120: 142-148.
Jonker D, Tang P, Kennecke H, …, Feilotter H, …, Seymour L. A Randomized Phase II Study of FOLFOX6/Bevacizumab With or Without Pelareorep in Patients With Metastatic Colorectal Cancer: IND.210, a Canadian Cancer Trials Group Trial. Clin Colorectal Cancer. 2018;17(3):231-239.e7.
Eigl B, Chi K, Tu D, …, Feilotter HE, Theis A, Seymour L. A randomized phase II study of pelareorep and docetaxel or docetaxel alone in men with metastatic castration resistant prostate cancer: CCTG study IND 209. Oncotarget. 2018;9(8):8155-8164.
Manley P, Abu-Abed S, Kirsch R, …, Feilotter H, …, Walia J. Familial PDGFRA-mutation syndrome: somatic and gastrointestinal phenotype. Hum Pathol. 2018;76:52-57.
Bernstein V, Ellard S, Dent S, …, Feilotter H, Hagerman L, Seymour L. A randomized phase II study of weekly paclitaxel with or without pelareorep in patients with metastatic breast cancer: final analysis of Canadian Cancer Trials Group IND.213. Breast Cancer Res Treat. 2018;167(2):485-493.
Lebo M, Zakoor K, Chun K, …, Feilotter HE, …, Lerner-Ellis J. Data sharing as a national quality improvement program: reporting on BRCA1 and BRCA2 variant-interpretation comparisons through the Canadian Open Genetics Repository (COGR). Genet Med. 2018;20(3):294-302.
Wang A, Ramjeesingh R, Chen C, …, Feilotter HE, Davey, S. Reduction in membranous immunohistochemical staining for the intracellular domain of epithelial cell adhesion molecule correlates with poor patient outcome in primary colorectal adenocarcinoma. Curr Oncol. 2016;23(3):e171-8.
Abraham KJ, Zhang X, Vidal R, …, Feilotter HE, Tron VA. Roles for miR-375 in Neuroendocrine Differentiation and Tumor Suppression via Notch Pathway Suppression in Merkel Cell Carcinoma. Am J Pathol. 2016;186(4):1025-35.
Dos santos vidal R, Hawrysh A, Walia JS, …, Feilotter H. Eligibility Criteria and Genetic Testing Results from a High-Risk Cohort for Hereditary Breast and Ovarian Cancer Syndrome in Southeastern Ontario. J Mol Diagn. 2016;18(3):362-369.
Mangone FR, Miracca EC, Feilotter HE, …, Nagai MA. ATM gene mutations in sporadic breast cancer patients from Brazil. Springerplus. 2015;4:23.
Feilotter HE, Michel C, Uy P, Bathurst L, Davey S. BRCA1 haploinsufficiency leads to altered expression of genes involved in cellular proliferation and development. PLoS ONE. 2014;9(6):e100068.
Geraci J, Dharsee M, Nuin P, …, Feilotter HE, Evans K. Exploring high dimensional data with Butterfly: a novel classification algorithm based on discrete dynamical systems. Bioinformatics. 2014;30(5):712-8.

See Dr. Feilotter’s recent publications on PubMed.

Research Areas

Biology Early Detection and Diagnosis

Disease Areas

Breast

Awards

Ontario Brain Institute, Top Achievement, 2017
Women in Cancer Research International Women’s Day write-up, 2017
The Pathologist, Cover Story, 2017
Canadians for Health Research, Researcher of the Month, 2016
Hamerton Service Award, Canadian College of Medical Geneticists, 2021

Opportunities to Collaborate

To collaborate with Dr. Feilotter, please contact her directly.

Collaborate with us

Visit OICR’s Collaborative Research Resources directory for more opportunities to collaborate with OICR researchers.

Programs

Ontario Molecular Pathology Research Network

A province-wide network of pathologists collaborating to carry out high-quality cancer research with a clear potential for clinical impact.

Learn More

In the News

Ontario experts chart vision to advance machine learning for cancer care

May 20, 2021

Funding from Ontario Institute for Cancer Research to help move research from experiment to impact

Aug 11, 2022

Low-cost molecular test targets more efficient brain cancer diagnosis

Jan 12, 2023

OPINION: A pathway to faster access to life-saving cancer innovations

Aug 01, 2024

Join our Mailing List